

9th August, 2022

To, Department of Corporate Services BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. Ref.: Scrip Code No. : 540701	To, The Manager, Listing Department, National Stock Exchange of India Ltd. “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref. : (i) Symbol – DCAL (ii) Series – EQ
--	--

SUB.: UN-AUDITED FINANCIAL RESULTS AND STATUTORY AUDITORS’ LIMITED REVIEW REPORT FOR THE QUARTER ENDED 30/06/2022

REF.: i) DISCLOSURE UNDER REGULATION 30 AND REGULATION 33 OF SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015
ii) OUR LETTER REGARDING REGULATION 29: INTIMATION OF BOARD MEETING DATED 2ND AUGUST, 2022

Dear Sir,

With reference to the above, we hereby inform that a Meeting of the Board of Directors of the Company was held today i.e. on Tuesday, the 9th day of August, 2022 which was commenced at 1.30 P.M. and concluded at 06:25 P.M., *inter alia*, have approved the Un-Audited Financial Results of the Company for the quarter ended 30th June, 2022, which is attached herewith along with Statutory Auditors’ Limited Review Report dated 9th day of August, 2022 signed by M/s. T R Chadha & Co LLP, Chartered Accountants, in respect of the Un-audited Financial Results of the Company for the quarter ended on 30th June, 2022, prepared in terms of Regulation 33 of SEBI (LODR) Regulations, 2015.

Kindly take this on your record.

Thanking you.

For, Dishman Carbogen Amcis Limited


Shrima Dave
Company Secretary



Encl.: As above

DISHMAN CARBOGEN AMCIS LIMITED

CIN : L74900GJ2007PLC051338 Email ID : grievance@imdcsl.com Web : www.imdcsl.com

Dishman Corporate House, Iscon - Bopal Road, Ambli, Ahmedabad 380 058 Phone No : 02717 - 420102 / 124

Part I : Statement of Unaudited Standalone / Consolidated Results for the Quarter Ended 30-06-2022

(Rupees in Crores / in Ten Million)

Sr. No.	PARTICULARS	STANDALONE			
		For The Quarter ended 30-06-2022	For The Preceding Quarter ended 31-03-2022	For The Corresponding Quarter ended 30-06-2021	For The Year ended 31-03-2022
		Unaudited	Audited (Refer note no. 3)	Unaudited	Audited
1	Total Income from operations (net)	103.61	83.34	62.87	302.79
2	Other Income	5.00	13.30	18.28	65.71
3	Total Income	108.61	96.64	81.15	368.50
4	Expenses				
	a) Cost of materials consumed	45.64	42.88	21.88	104.60
	b) Purchase of stock-in-trade	-	-	-	2.51
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(6.14)	(8.37)	(0.39)	(7.70)
	d) Employee benefits expense	22.85	20.00	16.68	80.54
	e) Finance costs	12.60	10.03	7.79	37.23
	f) Depreciation and amortisation expense	34.65	34.49	34.88	140.07
	g) Other Expenditure	38.70	27.61	20.66	88.65
	Total expenses	148.30	126.64	101.50	445.90
5	Profit / (Loss) before share of profit from associate & joint ventures ,exceptional items and Tax (3-4)	(39.69)	(30.00)	(20.35)	(77.40)
6	Share of Profit from associates and Joint Ventures	-	-	-	-
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	(39.69)	(30.00)	(20.35)	(77.40)
8	Exceptional items	-	3.41	-	5.91
9	Profit/(Loss) before tax (7-8)	(39.69)	(33.41)	(20.35)	(83.31)
10	Tax expense	(14.86)	(38.24)	(6.83)	(52.84)
	- Current Tax	-	-	-	-
	- Deferred tax Expenses/(Income)	(14.86)	(7.56)	(6.83)	(22.16)
	- Excess/(Short) provision of Income Tax of earlier years	-	(30.68)	-	(30.68)
11	Net Profit/(Loss) after tax (9-10) from Continued Business	(24.83)	4.83	(13.52)	(30.47)
12	Net Profit/(Loss) after tax from Discoutinued Business	-	-	(0.44)	(1.08)
13	Net Profit/(Loss) after tax	(24.83)	4.83	(13.96)	(31.55)
14	Other Comprehensive Income (Net of Tax)				
	(A) Other Comprehensive Income / (expenses) not to be reclassified to profit or loss-				
	(a) (i) Re measurement gains/ (Losses) on defined benefit plans	0.04	0.74		0.15
	(ii) Income Tax effect on above	(0.01)	(0.26)		(0.05)
	(b) (i) Changes in fair value of FVTOCI equity instruments	1.09	(396.00)	0.51	(395.12)
	(ii) Income Tax effect on above	(0.38)	8.61	(0.18)	8.30
	(B) Other Comprehensive Income / (expenses) to be reclassified to profit or loss-				
	(a) (i) Movement in Foreign currency translation reserve	-	-	-	-
	(b) (i) foreign exchange fluctuation in respect of cash flow hedge	(22.62)	(0.68)	(30.03)	(32.11)
	(ii) Income Tax effect on above	7.90	0.24	10.51	11.22
15	Total Comprehensive Income for the year (13+14) (Comprising Profit/ (Loss) and Other Comprehensive Income for the period)	(38.81)	(382.52)	(33.15)	(439.16)
16	Earning per equity share (face value of Rs. 2/-)				
	a) Basic (not annualised (except year end) for the quarter)	(1.58)	0.31	(0.89)	(2.01)
	b) Diluted (not annualised (except year end) for the quarter)	(1.58)	0.31	(0.89)	(2.01)
17	Paid up equity share capital (face value of Rs. 2/- each)	31.36	31.36	31.36	31.36
18	Other equity (excluding revaluation reserve) as at 31st March				4,200.42



DISHMAN CARBOGEN AMCIS LIMITED

CIN : L74900GJ2007PLC051338 Email ID : grievance@imdc.com Web : www.imdc.com

Dishman Corporate House, Iscon - Bopal Road, Ambli, Ahmedabad 380 058 Phone No : 02717 - 420102 / 124

Part I : Statement of Unaudited Consolidated Results for the Quarter Ended 30-06-2022

(Rupees in Crores / in Ten Million)

Sr. No.	PARTICULARS	CONSOLIDATED			
		For The Quarter ended 30-06-2022	For The Preceding Quarter ended 31-03-2022	For The Corresponding Quarter ended 30-06-2021	For The Year ended 31-03-2022
		Unaudited	Audited (Refer note no.3)	Unaudited	Audited
1	Total Income from operations (net)	540.61	568.99	550.73	2,140.69
2	Other Income	5.67	4.37	10.41	43.42
3	Total Income	546.28	573.36	561.14	2,184.11
4	Expenses				
	a) Cost of materials consumed	155.41	151.44	100.10	460.50
	b) Purchase of stock-in-trade	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(63.42)	(3.72)	28.37	(13.08)
	d) Employee benefits expense	256.38	252.59	239.03	981.49
	e) Finance costs	19.18	15.64	12.37	56.81
	f) Depreciation and amortisation expense	75.08	83.88	74.71	307.59
	g) Other Expenditure	101.86	128.25	82.59	361.98
	(h) SaaS IT project cost	2.09	18.43	-	18.43
	Total expenses	546.58	646.51	537.17	2,173.72
5	Profit / (Loss) before share of profit from associate & joint ventures ,exceptional items and Tax (3-4)	(0.30)	(73.15)	23.97	10.39
6	Share of Profit from associates and Joint Ventures	-	-	-	-
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	(0.30)	(73.15)	23.97	10.39
8	Exceptional items	-	(12.14)	-	(14.64)
9	Profit/(Loss) before tax (7-8)	(0.30)	(85.29)	23.97	(4.25)
10	Tax expense	(4.31)	(40.68)	7.95	(22.26)
	- Current Tax	13.21	(5.69)	13.51	21.73
	- Deferred tax	(17.52)	(4.31)	(5.56)	(13.31)
	- (Excess)/Short provision of Income Tax of earlier years	-	(30.68)	-	(30.68)
11	Net Profit/(Loss) after tax (9-10)	4.01	(44.61)	16.02	18.01
12	Other Comprehensive Income / Loss (Net of Tax)				
	(A) Other Comprehensive Income / (expenses) not to be reclassified to profit or loss-				
	(a) (i) Re measurement gains/ (Losses) on defined benefit plans	0.75	60.74	0.45	61.72
	(a) (ii) Income Tax effect	(0.01)	(7.50)	-	(7.29)
	(b) (i) Changes in fair value of FVTOCI equity instruments	1.09	(396.00)	0.51	(395.12)
	(b) (ii) Income tax effect	(0.38)	8.61	(0.18)	8.30
	(B) Other Comprehensive Income / (expenses) to be reclassified to profit or loss-				
	(a) (i) Movement in Foreign currency translation reserve	(9.09)	35.75	156.20	189.07
	(b) (i) foreign exchange fluctuation in respect of cash flow hedge	(22.62)	(0.68)	(30.03)	(32.11)
	(ii) Income tax relating to above	7.90	0.24	10.51	11.22
13	Total Comprehensive Income for the period/year (11+12) (Comprising Profit/ (Loss) and Other Comprehensive Income for the period)	(18.35)	(343.44)	153.48	(146.20)
14	Profit / (Loss) for the period attributable to :				
	(a) Owners of the company	4.01	(44.61)	16.02	18.01
	(b) Non Controlling Interest	-	-	-	-
	Profit for the period/year	4.01	(44.61)	16.02	18.01
15	Other Comprehensive Income for the period/year attributable to:				
	(a) Owners of the company	(22.36)	(298.84)	137.46	(164.20)
	(b) Non Controlling Interest	-	-	-	-
	Other Comprehensive Income	(22.36)	(298.84)	137.46	(164.20)
16	Total Comprehensive Income for the period/year attributable to:				
	(a) Owners of the company	(18.35)	(343.45)	153.48	(146.20)
	(b) Non Controlling Interest	-	-	-	-
	Total Comprehensive Income	(18.35)	(343.45)	153.48	(146.20)
17	Earning per equity share (face value of Rs. 2/-)				
	a) Basic (not annualised (except year-end) for the quarter)	0.26	(2.85)	1.02	1.15
	b) Diluted (not annualised (except year end) for the quarter)	0.26	(2.85)	1.02	1.15
18	Paid up equity share capital (face value of Rs. 2/- each)	31.36	31.36	31.36	31.36
19	Other equity (excluding revaluation reserve) as at 31st March				5,517.58

For and on behalf of the board



(Handwritten signature)

Arpit J. Vyas
Global Managing Director
DIN : 01540057

Place: Ahmedabad
Date: 9th August, 2022



Notes:

1. The Financial results (standalone and consolidated) have been reviewed by the Audit Committee and taken on record by the Board of Directors at their meetings held on 9th August, 2022. These financial results (standalone and consolidated) have been prepared in compliance with Ind AS as notified by the Ministry of Corporate Affairs and prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting pronouncements generally accepted in India, to the extent applicable.
2. Statutory Auditors have carried out limited review of standalone as well as consolidated financial results of the Company for the quarter ended 30th June, 2022.
3. The figures for the quarter ended 31st March, 2022 are the balancing figures between the audited figures in respect of the full financial year and the reviewed year-to-date figures up to the third quarter of the financial year 2021-22.

4. The amalgamation held between Dishman Pharmaceuticals and Chemical Limited and Dishman Care Limited into Dishman Carbogen Amcis Limited accounted in the year 2016-17 under the "Purchase Method" as per the then prevailing Accounting Standard 14 – Accounting for Amalgamations, as referred to in the Scheme of Amalgamation approved by the Hon'ble High Court, Gujarat, which is different from Ind AS 103 "Business Combinations". The excess of consideration payable over net assets acquired had been recorded as goodwill amounting to INR 1,326.86 crores, represented by underlying intangible assets acquired on amalgamation and is being amortized over the period of 15 years from the Appointed Date i.e. 1st January, 2015.

Had the goodwill not been amortized as required under Ind AS 103, the Depreciation and Amortization expense for the quarter ended 30th June, 2022, 31st March, 2022, 30th June, 2021 and for the year ended 31st March, 2022 would have been lower by INR 22.05 crores, INR 21.81 crores, INR 22.05 crores and INR 88.45 crores, respectively, and the Profit Before Tax for the corresponding periods would have been higher by an equivalent amount. Goodwill amounting to INR 663.52 Crores is outstanding as on 30th June, 2022. Had the goodwill not been amortized, assets of the company would have been higher by INR 663.34 Crores.

5. The Company has opted to publish only consolidated financial results in the news paper. The stand-alone financial results are available for perusal on the Company's website: www.imdcal.com as well as on the Stock Exchange's websites i.e. on www.bseindia.com and www.nseindia.com.
6. Group is required to disclose segment information based on the 'management approach' as defined in Ind AS 108- Operating Segments, which is how the Chief Operating Decision Maker (CODM) evaluates the Group's performance and allocates resources based on the analysis of the various performance indicators. CODM reviews the results of the Group engaged in the business of Contract Research and Manufacturing Services (CRAMS), quats, specialty chemicals, Vitamins D3 and its analogues, cholesterols, disinfectants etc. Accordingly, Group as a whole is a single segment. The information as required under Ind AS 108 is available directly from the financial statements, hence no separate disclosure has been made.
7. During the quarter, upon application made by the Company, name of the wholly owned subsidiary viz. Dishman Australasia Pty Ltd. has been struck-off, which was dormant since long.
8. Consolidated financial results comprise the results of the parent Company, Dishman Carbogen Amcis Limited and its subsidiaries (together referred as "the Group") viz. Dishman CARBOGEN



AMCIS (Europe) Ltd., (formerly known as Dishman Europe Limited), Dishman USA Inc., Dishman International Trading (Shanghai) Co. Ltd, CARBOGEN AMCIS Holdings AG. (formerly known as Dishman Pharma Solutions AG), Switzerland; CARBOGEN AMCIS (Shanghai) Co. Ltd. [formerly known as Dishman Pharmaceuticals & Chemicals (Shanghai) Co. Ltd.], Shanghai Yiqian International Trade Co. Ltd.; CARBOGEN AMCIS BV (formerly known as "Dishman Netherlands B. V."), Carbogen Amcis Ltd., U.K., CARBOGEN AMCIS AG, Switzerland, CARBOGEN AMCIS SAS, Dishman Middle East (FZE); Dishman Carbogen Amcis (Japan) Ltd. (formerly known as "Dishman Japan Limited"), Dishman Carbogen Amcis (Singapore) Pte. Ltd.; Dishman Biotech Ltd.; CARBOGEN AMICS Specialities AG.; CARBOGEN AMICS Innovations AG.; DISHMAN CARBOGEN AMCIS AG.; CARBOGEN AMCIS Real Estate and Visible Investment Private Limited.

9. There was a joint inspection carried out during the quarter ending March, 2020 by the Swissmedic and European Directorate for the Quality of Medicines & HealthCare (EDQM), due to which there were certain audit observations issued deficient to EU GMP Part II and other relevant Annexes for the Company's Bavla site. There was an impact on the production at the Company's Bavla manufacturing site due to the observations received, which impacted the revenue and profitability of the Company's operations at Bavla since March 2020 till now.

The Company has been steadily ramping up manufacturing activities at the Bavla site in order to meet the customer requirements including successfully passing certain key customer audits at the Company's Bavla site. The implementation of the Corrective Action Plan submitted to the EDQM is also underway and on track wherein the company should be able to successfully address the audit observations.

10. The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits has received Presidential assent and has been published in the Gazette of India. However, the effective date of the Code and final rules for quantifying the financial impact are yet to be notified. The Group will assess the impact of the Code when relevant provisions are notified and will record related impact, if any, in the period the Code becomes effective.
11. The previous quarter / year figures have been re-grouped, re-cast and re-arranged wherever considered necessary to make it comparable.

Place: Ahmedabad
Date: 9th August, 2022



On behalf of the Board of Directors

Arpit Vyas
Global Managing Director
DIN - 01540057



Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**TO THE BOARD OF DIRECTORS OF
DISHMAN CARBOGEN AMCIS LIMITED**

1. We have reviewed the accompanying "Statement of Unaudited Standalone Financial Result of **Dishman Carbogen Amcis Limited** ("the Company") for the quarter ended June 30,2022" ("the statement") attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of The SEBI (Listing Obligation and Disclosure Requirements) Regulation,2015, as amended ('the Listing Regulation'), read with SEBI Circular No. CIRICFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').
2. The preparation of the Statement is in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.



T R Chadha & Co., a partnership firm converted into T R Chadha & Co LLP
(A limited liability partnership with LLP Identification No. AAF-3926) with effect from 28th December, 2015

Ahmedabad Branch : 301, 3rd Floor, Indraprasth Corporate, Opp. Shell Petrol Pump, Anandnagar Road, Prahladnagar, Ahmedabad-380 015. Tele. : 079-66171697, 079-4800 4897 Email : ahmedabad@trchadha.com

Regd Office : Suite No-11A, 2nd Floor, Gobind Mansion, H Block, Connaught Circus, New Delhi - 110 001. Tele. : 011 41513059 / 41513169

Head Office : B-30, Connaught Place, Kuthiala Building, New Delhi-110 001. Email : delhi@trchadha.com

Branches at : ♦ MUMBAI ♦ HYDERABAD ♦ PUNE ♦ CHENNAI ♦ BENGALURU ♦ GURGAON ♦ TIRUPATI



5. We draw attention to Note 4 of the Statement detailing the accounting treatment relating to the scheme Involving merger of Dishman Pharmaceuticals and Chemicals Limited and Dishman Care Limited with Dishman Carbogen Amcis Limited, which has been accounted in the year 2016-17 under the "Purchase Method" as per the then prevailing Accounting Standard 14 - Accounting for Amalgamation (AS 14) in compliance with scheme of Amalgamation pursuant to Section 391 to 394 of Companies Act, 1956 Approved by Hon'ble High Court of Gujarat in accordance with the scheme, the company had recognized goodwill on Amalgamation amounting to ₹ **1,326.86 Crores** which is amortized over the period of 15 years from the appointed date i.e., January 01, 2015. This accounting treatment is different from that prescribed under Indian Accounting Standard (Ind-AS 103) - 'Business Combinations'. Had the goodwill not been amortized as required under Ind As 103, the Depreciation and Amortization expense for the quarter ended June 30, 2022 would have been lower by ₹ **22.05 Crores** and profit before tax for the quarter ended June 30, 2022 would have been higher by equivalent amount. Goodwill amounting to ₹ **663.52 Crores** is outstanding as on June 30, 2022. Had the goodwill not been amortized, assets of the company would have been higher by ₹ **663.34 Crores**.
6. We draw attention to Note 9 in relation to certain audit observation issued by the Swissmedic and European Directorate for the quality of medicines & Healthcare (EDQM) on account of joint inspection carried out by them for the Company's manufacturing plant at Bavla and certain Certificate of suitability (CEPs) were also suspended. As a result, Company's operations, production, revenue and profitability were adversely impacted during the quarter.

Our opinion is not modified in respect of these matters.

For, T R Chadha & Co LLP
Chartered Accountants
Firm Regn. No: 006711N / N500028

Brijesh Thakkar
(Partner)
M. No.: 135556
UDIN: - 22135556AOQSPC8947



Place: Ahmedabad
Date: August 09, 2022

T R Chadha & Co., a partnership firm converted into T R Chadha & Co LLP
(A limited liability partnership with LLP Identification No. AAF-3926) with effect from 28th December, 2015

Ahmedabad Branch : 301, 3rd Floor, Indraprasth Corporate, Opp. Shell Petrol Pump, Anandnagar Road, Prahladnagar, Ahmedabad-380 015. Tele. : 079-66171697, 079-4800 4897 Email : ahmedabad@trchadha.com

Regd Office : Suite No-11A, 2nd Floor, Gobind Mansion, H Block, Connaught Circus, New Delhi - 110 001. Tele. : 011 41513059 / 41513169

Head Office : B-30, Connaught Place, Kuthiala Building, New Delhi-110 001. Email : delhi@trchadha.com

Branches at : ♦ MUMBAI ♦ HYDERABAD ♦ PUNE ♦ CHENNAI ♦ BENGALURU ♦ GURGAON ♦ TIRUPATI



Independent Auditor's Review Report on Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**To the Board of Directors
Dishman Carbogen Amcis Limited**

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **Dishman Carbogen Amcis Limited** ("the Holding Company") and its subsidiaries (the Holding Company and its Subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2022 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, as amended ('the Listing Regulation') read with SEBI Circular No. CIRICFD/CMD1/44/2019 dated March 29,2019 ('the Circular').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting standard 34 (Ind AS 34) "Interim Financial Reporting", prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the statement in accordance with the standard on review Engagements (SRE) 2410 "Review of interim Financial Information performed by the Independent Auditor of the Entity.", issued by the Institute of Chartered accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



T R Chadha & Co., a partnership firm converted into T R Chadha & Co LLP
(A limited liability partnership with LLP Identification No. AAF-3926) with effect from 28th December, 2015.

Ahmedabad Branch : 301, 3rd Floor, Indraprasth Corporate, Opp. Shell Petrol Pump, Anandnagar Road, Prahladnagar, Ahmedabad-380 015. Tele. : 079-66171697, 079-4800 4897 Email : ahmedabad@trchadha.com

Regd Office : Suite No-11A, 2nd Floor, Gobind Mansion, H Block, Connaught Circus, New Delhi - 110 001.
Tele. : 011 41513059 / 41513169

Head Office : B-30, Connaught Place, Kuthiala Building, New Delhi-110 001. Email : delhi@trchadha.com

Branches at : ♦ MUMBAI ♦ HYDERABAD ♦ PUNE ♦ CHENNAI ♦ BENGALURU ♦ GURGAON ♦ TIRUPATI



We also performed procedures in accordance with the circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33 (8) of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 as amended to the extent applicable.

4. The statement includes the results of the following entities;

Holding Company	Dishman Carbogen Amcis Limited
Subsidiary Companies	Dishman Middle East FZE, Dishman USA Inc., Dishman Carbogen Amcis (Europe) Ltd, Dishman Carbogen Amcis (Singapore) Pte Ltd, Carbogen Amcis Holding AG, Dishman International Trading (Shanghai) Co. Ltd., Dishman Biotech Ltd
Stepdown Subsidiary Companies	Carbogen Amcis Specialities AG, Carbogen Amcis Innovations AG, Shanghai Yiqian International Trade Co Ltd, Visible Investment Pvt Limited, Dishman Carbogen Amcis AG
Step Stepdown Subsidiary Companies	Carbogen Amcis B.V., Carbogen Amcis Real Estate, Carbogen Amcis AG, Carbogen Amcis SAS, Carbogen Amcis Ltd, Carbogen Amcis (Shanghai) Co Ltd, Dishman Carbogen Amcis (Japan) Ltd

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the information given by management referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting standard ('Ind AS') and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and disclosure Requirements) Regulations 2015, as amended including the manner in which it is to be disclosed, or that it contain any material misstatement.
6. The accompanying statement includes interim financial results / financial information in respect of 19 subsidiaries whose interim financial results / financial information reflects, total revenues of ₹ **570.83 Crores**, total net profit after tax of ₹ **33.53 Crores** and total comprehensive Income of ₹ **34.24 Crores** for the quarter ended June 30, 2021. This interim financial results have been reviewed by other auditors whose reports have been furnished to us by the management and


T R Chadha & Co., a partnership firm converted into T R Chadha & Co LLP
(A limited liability partnership with LLP Identification No. AAF-3926) with effect from 28th December, 2015

Ahmedabad Branch : 301, 3rd Floor, Indraprasth Corporate, Opp. Shell Petrol Pump, Anandnagar Road, Prahladnagar, Ahmedabad-380 015. Tele. : 079-66171697, 079-4800 4897 Email : ahmedabad@trchadha.com

Regd Office : Suite No-11A, 2nd Floor, Gobind Mansion, H Block, Connaught Circus, New Delhi - 110 001, Tele. : 011 41513059 / 41513169

Head Office : B-30, Connaught Place, Kuthiala Building, New Delhi-110 001. Email : delhi@trchadha.com

Branches at : ♦ MUMBAI ♦ HYDERABAD ♦ PUNE ♦ CHENNAI ♦ BENGALURU ♦ GURGAON ♦ TIRUPATI





our report on the statement, in so far it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Certain of these subsidiaries are located outside India whose financial results have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by their respective independent auditors under generally accepted auditing standards applicable in their respective countries. The Holding company's management has converted the financial results of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our opinion in so far as it relates to the balances and affairs of such subsidiaries located outside India is based on the report of their respective independent auditors and the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

Our report on the statement is not modified in respect of the above matters.

7. (a) We draw attention to Note 4 of the Statement detailing the accounting treatment relating to the scheme Involving merger of Dishman Pharmaceuticals and Chemicals Limited and Dishman Care Limited with Dishman Carbogen Amcis Limited, which has been accounted in the year 2016-17 under the "Purchase Method" as per the then prevailing Accounting Standard 14 – Accounting for Amalgamation (AS 14) in compliance with scheme of Amalgamation pursuant to Section 391 to 394 of Companies Act, 1956 approved by Hon'ble High Court of Gujarat. In accordance with the scheme, the company had recognized goodwill on Amalgamation amounting to ₹ **1,326.86 Crores** which is amortized over its useful life. This accounting treatment is different from that prescribed under Indian Accounting Standard (Ind AS 103) "Business Combinations". Had the goodwill not been amortized as required under Ind AS 103, the Depreciation and Amortization expense for the quarter ended June 30, 2022 would have been lower by ₹ **22.05 Crores** and profit before tax for the quarter ended June 30, 2022 would have been higher by an equivalent amount. Goodwill amounting to ₹ **663.52 Crores** is outstanding as on June 30, 2022. Had the goodwill not amortized, assets of the company would have been higher by ₹ **663.34 Crores**.



T R Chadha & Co., a partnership firm converted into T R Chadha & Co LLP
(A limited liability partnership with LLP Identification No. AAF-3926) with effect from 28th December, 2015

Ahmedabad Branch : 301, 3rd Floor, Indraprasth Corporate, Opp. Shell Petrol Pump, Anandnagar Road, Prahladnagar, Ahmedabad-380 015. Tele. : 079-66171697, 079-4800 4897 Email : ahmedabad@trchadha.com

Regd Office : Suite No-11A, 2nd Floor, Gobind Mansion, H Block, Connaught Circus, New Delhi - 110 001.
Tele. : 011 41513059 / 41513169

Head Office : B-30, Connaught Place, Kuthiala Building, New Delhi-110 001. Email : delhi@trchadha.com

Branches at : ♦ MUMBAI ♦ HYDERABAD ♦ PUNE ♦ CHENNAI ♦ BENGALURU ♦ GURGAON ♦ TI RUPATI



(b) We draw attention to Note 9 of the statement in relation to certain audit observation issued by the Swissmedic and European Directorate for the quality of medicines & Healthcare (EDQM) on account of joint inspection carried out by them for the Company's manufacturing plant at Bavla and certain Certificate of suitability (CEPs) were also suspended. As a result, Company's operations, production, revenue and profitability were adversely impacted during the quarter.

Our report on the statement is not modified in respect of the above matters.

For, T R Chadha & Co LLP
Chartered Accountants
Firm Regn. No: 006711N / N500028

Brijesh Thakkar
(Partner)
M. No.: 135556



UDIN: - 22135556AOQREY6610
Place: Ahmedabad
Date: August 09, 2022

T R Chadha & Co., a partnership firm converted into T R Chadha & Co LLP
(A limited liability partnership with LLP Identification No. AAF-3926) with effect from 28th December, 2015

Ahmedabad Branch : 301, 3rd Floor, Indraprasth Corporate, Opp. Shell Petrol Pump, Anandnagar Road, Prahladnagar, Ahmedabad-380 015. Tele. : 079-66171697, 079-4800 4897 Email : ahmedabad@trchadha.com

Regd Office : Suite No-11A, 2nd Floor, Gobind Mansion, H Block, Connaught Circus, New Delhi - 110 001. Tele. : 011 41513059 / 41513169

Head Office : B-30, Connaught Place, Kuthiala Building, New Delhi-110 001. Email : delhi@trchadha.com

Branches at : ♦ MUMBAI ♦ HYDERABAD ♦ PUNE ♦ CHENNAI ♦ BENGALURU ♦ GURGAON ♦ TIRUPATI
